

Review Article

Major Histocompatibility Complex (MHC) Diversity and its implications for human and wildlife health and Conservation – A review

Oluwakayode Michael COKER^{1*}, Osamede Henry OSAIYUWU², Abraham Oladiran FATOKI²

¹Department of Wildlife and Ecotourism Management, University of Ibadan, Nigeria

²Department of Animal Science, University of Ibadan, Nigeria

* Corresponding author: Oluwakayode Michael Coker, University of Ibadan, Nigeria +2348054150061, liftingup2003@gmail.com

Article history: Received: September 28th 2022; Revised: May 22nd 2023; Accepted: June 11th 2023

Abstract

It is clear that the global environment has changed and is still changing. The results of climate change, pollution, human use, and misuse of natural resources are tolling on humans and global biodiversity. The appropriate response(s) to these changes can be attributed to the efficacy of the immune system. The Major Histocompatibility Complex (MHC) has a key role in maintaining global biodiversity in the face of obvious threats. Genetic variation, especially those within MHC proteins has been known to influence the ability of individuals to cope with various pathogens. In this review, we reveal from empirical research, the diversities within the MHC in wildlife, highlight the importance of MHC to wildlife and human health, emphasize the need to conserve MHC diversity for adequate conservation, and open a discussion on whether the interplay between the MHC genes and disease resistance is a question of quantity or quality. For most jawed vertebrates, classical MHC genes are the most gene-dense and polymorphic. This polymorphism in the MHC genes can be explained by host-pathogen coevolution and provides an excellent tool for determining a population's or species' immunological fitness. Their variation is undoubtedly adaptively important, and there is strong evidence that pathogen-imposed balancing selection is the primary cause of its maintenance. Over the years, variants in the MHC have been reported as major risk factors for autoimmune and infectious diseases in humans and wildlife species of conservation concern. It has been observed that, though high diversity within the MHC proffers some protection for most natural populations, this seems not to be universal. The influence of this high diversity on the survival of natural populations should be further investigated. As the debate lingers, there is a dire need to protect the present diversity at the locus. This will definitely play a very important role in maintaining the health of both humans and animals and ensuring the conservation of biodiversity in response to the inevitable changes in our world.

Keywords: Biodiversity health, Conservation, Genetic variations, Immune genes

Introduction

Selective processes require genetic diversity as a starting point. Populations with high levels of diversity are better able to respond to threats like pathogens and predators, as well as long-term effects like environmental change (Wang, 2017). Low genetic diversity, on the other hand, may hinder a population's ability to respond to these threats over time (Hedrick, 2002). Genetic diversity measures are frequently based on neutral markers, e.g., microsatellites (Sommer, 2005), while adaptive markers, such as genes of the major histocompatibility complex (MHC), are better reflected by genetic diversity to capture information about population conservation (Holderegger *et al.*, 2006; De Bruyn, 2007; Piertney and Webster, 2010).

It is crystal clear that the global environment has changed and is still changing. The results of climate change, pollution, human use, and misuse of natural resources are tolling on humans and global biodiversity. The appropriate response(s) to these changes can be attributed to the immune system's efficacy. Diversity within the Major Histocompatibility Complex (MHC) has a key role in maintaining

global biodiversity in the face of the obvious threats they face. Genetic variation, especially those within MHC proteins has been known to influence the ability of individuals to cope with various pathogens (Castillo *et al.*, 2010; de Groot *et al.*, 2017).

Though previous studies of MHC diversity have primarily focused on the allelic level (Hedrick, 2003; Kalbe *et al.*, 2009; Thoss *et al.*, 2011), the distinguishing feature of classical MHC genes is their extreme polymorphism (Piertney and Oliver, 2006; Schwensow *et al.*, 2007). As revealed by the high relative nonsynonymous substitution rate inside the peptide-binding domain (PBD) (Hughes *et al.*, 1990), notably at peptide binding sites (PBS) (Reche and Reinhertz, 2003) as well as large short-term selection coefficients, polymorphism evolves adaptively (Schwensow *et al.*, 2007; Biedrzycka and Radwan, 2008). MHC genes are useful for investigating how selection might produce and sustain genetic variation in natural populations because of their high polymorphism and evidence of positive selection (Radwan *et al.*, 2020). Given MHC's key function in the immune system of vertebrates, pathogen-driven selection may be more viable to decipher the high MHC diversity (Ziegler *et al.*, 2005) seen in most vertebrates. Because of gene duplication, recombination, and conversion, alleles from different MHC loci, particularly in birds and reptiles, can be very similar and even identical to each other (Burri *et al.*, 2010; Gaigher *et al.*, 2016), and gene copy numbers can also vary between individuals (Gaigher *et al.*, 2016; Tsuji *et al.*, 2017). MHC genes are often duplicated in fish, reptiles, birds, and mammals, with 1–9 copies and 1–1,400 alleles per gene (Babik *et al.*, 2005; Huchard *et al.*, 2006; Castro-Prieto *et al.*, 2011). Apart from the challenges posed by duplications and allelic variation, genotyping adequate sample sizes in a population for MHC-related studies can be time-consuming and costly.

In addition, human MHC differs significantly from other animals in terms of the quantity and organization of genes and are thought to have experienced large-scale duplication events, leaving paralogous sets of genes on chromosomes 1, 9, and 19. MHC class I is found in all mammals, however, a lack of orthology suggests several rounds of gene duplication and loss during evolution (Yamaguchi and Dijkstra, 2019).

Furthermore, balancing selection on MHC genes has revealed a pattern of trans-species polymorphism, which has resulted in the maintenance of MHC allelic lineages among related species for prolonged periods. Some vertebrate species have been found to have low MHC variation in wild populations that have experienced population reduction in the past (Castillo *et al.*, 2010; Castro-Prieto *et al.*, 2011; Niskanen *et al.*, 2014; Kohyama *et al.*, 2015), making them vulnerable to pathogens and increasing the risk of extinction (Niskanen *et al.*, 2014). However, inbred populations have minimal MHC variation, leading to reduced parasite resistance (Radwan *et al.*, 2010). Characterization of MHC genes is important in measuring the health of natural populations, which in no small way contributes to biodiversity conservation (Ujvari and Belov, 2011; de Groot *et al.*, 2017). This review, therefore, explores the diversities within the MHC in wildlife, highlights the importance of MHC to wildlife and human health, emphasizes the need to protect/conservate MHC diversity in wildlife for adequate conservation, and opened a discussion on whether the diversity within the MHC genes and disease resistance is a question of quantity or quality.

Genetics of MHC

The MHC is a large gene cluster in the vertebrate genome that codes for cell surface proteins, which are utilized by the immune system. In vertebrates, MHC is vital for reacting to antigens and initiating an immune response. The bulk of the research that has addressed immune genes in wild populations has concentrated mainly on the MHC genes as a single family, which is a crucial component of adaptive immunity (Morris *et al.*, 2015). MHC diversity has been related to a range of fitness features, including parasite resistance, survival, and reproductive success, which all have implications for population viability (Sommer, 2005; Ujvari and Belov 2011; Manlik *et al.*, 2019).

The MHC is a multi-gene family in birds and mammals that consists of two tightly linked subclasses that play a key role in the initiation of the immune response (Yamaguchi and Dijkstra,

2019). It spans 4 million base pairs and is traditionally divided into three regions: class I, class II, and class III, or the inflammatory region (Sommer, 2005). MHC, also known as human leukocyte antigen (HLA), is the most polymorphic gene cluster in the human genome, with more than 200 genes encoding various aspects of the immunological response mechanism. It is located on the short arm of chromosome 6 and consists of about 4,000 kilobases of DNA covering about 2.5 map units (Ujvari and Belov, 2011).

The MHC complex is one of the most diverse in the vertebrate genome. Most of its diversity is concentrated in the functionally essential peptide binding region (PBR), which binds peptides and exposes them to T-cells, triggering the required immunological response (Piertney and Oliver, 2006). MHC genes code for proteins that identify "self" peptides from "non-self" peptides (Piertney and Oliver, 2006). Individuals express only a small number of distinct MHC molecules, in contrast to the huge population diversity of MHC molecules. This is thought to be a trade-off between enhancing the detection of foreign antigens and limiting the loss of T cell clones during thymus self-tolerance induction. Immune recognition, vulnerability to viral and autoimmune disorders, kin recognition, individual odors, mating preferences, and pregnancy outcome are all influenced by MHC variations (Sommer, 2005).

For most jawed vertebrates, classical MHC genes are the most diverse genes (Hughes and Hughes, 1995), and are scattered throughout a large genomic region with varying levels of recombination with other genes (Radwan *et al.*, 2020).

MHC and human health

The MHC-encoded glycoproteins in humans are known as human leukocyte antigen (HLA) and the best-characterized function of MHC-encoded molecules is the presentation of antigenic peptides to T cell receptors (TCR) on cognate T-cells (Tsai and Santamaria, 2013). The MHC genes are the most variable in the human genome, and the function of HLA molecules is to present peptides from invasive organisms (Robinson *et al.*, 2015). The HLA molecules are slightly different from each other in their amino acid sequences leading to different structures in the peptide-binding cleft (Mosaad, 2015). In an immune response, T cells become activated upon interacting with the foreign antigen/HLA complex (Bose *et al.*, 2013). Upon activation, the immune response is elicited as a result of the interaction between the cytokines release and the T cells, and this will lead to the recognition and destruction of cells with the same foreign antigen/HLA complex when next encountered (Mosaad, 2015). HLA Class I and HLA Class II antigens behave differently in this process in terms of their precise mechanism of action. By their existence on all nucleated cells, HLA Class I molecules present antigens that are peptides generated by invading viruses. These are delivered to CD8 T lymphocytes (Tsai and Santamaria, 2013), which will then kill the infected cell immediately.

Over time, the largest number of connections between human disease and the MHC region of the genome have been documented. However, the significance of MHC genes extends beyond immunological disorders as it also affects other infectious diseases (Howell, 2013). The MHC shows associations with most autoimmune diseases as well as many inflammatory and infectious diseases [such as Hodgkin's lymphoma (Amiel, 1967), Acute lymphocytic leukaemia (Walford *et al.*, 1970), Ankylosing spondylitis (Brewerton *et al.*, 1973), Psoriasis (Zhou and Zhang, 2018), Myasthenia gravis (Hjelmström and Sanjeevi, 2000), Malaria (Riley *et al.*, 1992), Dengue shock syndrome (Khor *et al.*, 2011), Sialidosis (Milner *et al.*, 1997), Complement deficiencies (Truedsson *et al.*, 1993), Congenital adrenal hyperplasia (Fleischnick *et al.*, 1983), Sarcoidosis (Judson, 2018), Type 1 diabetes (Morran *et al.*, 2015), Rheumatoid arthritis (Newton *et al.*, 2004), Systemic lupus erythematosus (Fernando *et al.*, 2007; Fernando *et al.*, 2012), Multiple sclerosis (Ramagopalan *et al.*, 2009), Pemphigus vulgaris (Delgado *et al.*, 1996), Leprosy (Gorodezky *et al.*, 2004), Narcolepsy (De la Herrán-Arita and García-García, 2014), Ulcerative colitis (Zhang *et al.*, 2019), Graves' disease (Chu *et al.*, 2018), Celiac disease (Gutierrez-Achury *et al.*, 2015), Selective IgA deficiency (Wang

et al., 2011), Bare lymphocyte syndrome (Reith and Mach, 2001), and Juvenile myoclonic epilepsy (Wong et al., 2001)].

Importance of MHC on animals

A good number of natural populations are threatened by a sharp decline in the total amount of habitat that is available, and also by an increase in habitat fragmentation and degradation. These cause populations to shrink in size and restrict gene flow among subpopulations. (Peacock and Smith, 1997). Understanding the mechanisms that influence genetic variation and differentiation in endangered species is critical for evolutionary processes and conservation efforts (Sommer, 2005; Piertney and Oliver, 2006). The MHC genes, because of their characteristic polymorphism and their association with fitness, have become a valuable adaptive marker (Lan et al., 2019). MHC is a genetic system that can be used to examine disease dynamics in animals (Janeway et al., 2001). MHC research has focused on wildlife species that have witnessed population reduction due to diseases and human activities e.g., common frog (*Rana temporaria*) (Zeisset and Beebee, 2009), Eurasian beaver (*Castor fiber*) (Babik et al., 2005), lemur (*Microcebus murinus*) (Averdam et al., 2011), chacma baboon (*Papio ursinus*) (Huchard et al., 2006), sea lion (*Zalophus californianus*) (Bowen et al., 2004), giant panda (*Ailuropoda melanoleuca*) (Zeng et al., 2007), raccoon (*Procyon lotor*) (Castillo et al., 2010), cheetah (*Acinonyx jubatus*) (Castro-Prieto, 2011), European mink (*Mustela lutreola*) (Becker et al., 2009), and red-crowned crane (*Grus japonensis*) (Akiyama et al., 2017). Studying MHC variation in these species has widened our understanding of the immune response of host species to pathogens. On endangered species, MHC markers have been utilized (Miller et al., 2010; Mason et al., 2011). Individual variation in parasite load (Madsen and Ujvari, 2006; Schwensow et al., 2007), local adaptations (Evans et al., 2009), maternal-fetal interactions (Hedrick and Thomson, 1988), and lifetime reproductive success (Kalbe et al., 2009) are associated with MHC genes, making them useful molecular markers for assessing the status of endangered wildlife populations when conducting conservation programs.

Comparison between Wildlife and human MHC as it relates to their health

Nonhuman primate MHCs are identical to human MHCs, even though they contain a distinct number of MHC class I chain-related (MIC) genes (Dadi et al., 2015). The MIC has a structure that is comparable to that of classical MHC class I molecules. MIC proteins are made up of six exons that code for one transmembrane, one cytoplasmic, and three external ($\alpha 1-3$) domains (Jinushi et al., 2008).

The MIC in humans is expressed in a variety of immune cells as well as most epithelial tissues. Only freshly isolated endothelium cells, fibroblasts, and gastric epithelium were found to express MIC on the cell surface. When triggered with cellular stress inducers, however, reports showed up-regulation of MIC transcripts and cell surface protein expression in various cell lines (Molinero et al., 2002). Unlike humans, chimpanzees contain a single fused MICA/MICB gene, and MIC genes in less closely related primates may not be orthologous and are duplicated. Only MICA and MICB, both centromeric to HLA-B, are functioning MIC genes in humans (Al Hadra et al., 2022).

The MIC genes' relevance has been highlighted by their role in a variety of human diseases. Several researchers have found plausible links between MHC genes and diseases. For instance, Cohen et al. (2002) found a substantial link between particular MICA alleles and autoimmune illnesses like Behçet's disease. The MICA alleles have also been linked to resistance and susceptibility to human brucellosis (Bravo et al., 2007). Therefore, understanding the links among genetic diversities, immune resistance and susceptibility to pathogenic diseases, requires research into the diversity and evolution of MHC genes (Dadi et al., 2015).

Diversity within the MHC genes and disease resistance: A question of quantity or quality?

As intellectually appealing as the principles explaining MHC polymorphism and disease resistance is, the majority of the empirical data came from investigations involving humans or in animal experiments

(Froeschke and Sommer, 2005) and very few cases of associations between particular MHC alleles and parasite resistance have been reported in natural populations (Kelly and Trowsdale, 2017). However, the primary use of MHC genes in conservation has been to quantify the genetic diversity of natural populations, with no specific conservation implications (Ujvari and Belov, 2011). MHC diversity is substantial in most natural populations, in terms of number of the alleles, sequence variation, and heterozygosity (Hedrick, 2003). Characterization of polymorphic and polygenic MHC genes is thus a great indicator of genetic health and has applications in conservation biology, such as managing captive breeding programs for endangered species (De Groot et al., 2017).

Natural populations usually reveal high diversity within their MHC. Allelic variations leading to high levels of heterozygosity are usually observed in the MHC of most natural populations (Hedrick, 2003), which tend to proffer protection against pathogens and diseases. But this seems not to be universal. For example, bottlenecked populations of, Scandinavian beavers (*Castor fiber*), fallow deer (*Cervus dama*), and Northern elephant seals (*Mirounga angustirostris*) show no indication of increased susceptibility to infectious diseases despite their low polymorphisms in MHC genes (Weber et al., 2004). Also, Castro-Prieto et al. (2011) concluded that the low level of MHC diversity in free-ranging cheetahs (*Acinonyx jubatus*), in Namibia does not influence their immune-competence. Whereas, bottlenecked populations of desert bighorn sheep (*Ovis aries*), which show high levels of MHC diversity are also highly susceptible to many infectious diseases (Gutierrez-Espeleta et al., 2001). Apparently, the influence of the diversity within the MHC on the survival of natural populations, especially on disease resistance, requires a deeper look (Radwan et al., 2010). Is it a question of quality or quantity?

Need to protect MHC diversity

The major histocompatibility complex (MHC) is a molecule that allows the immune system to recognize and eradicate pathogenic infections. Infectious pathogens are now regarded to be the primary selective mechanism driving and maintaining the MHC's incredible diversity. To combat emerging pathogenic threats and ensure biological systems' long-term survival, high levels of MHC polymorphism must be maintained (Sommer, 2005; Piertney and Oliver, 2006; Alcaide et al., 2010). The facts that

- (1) selection impacts allele frequencies in small populations
- (2) frequency-dependence and heterozygote advantage are losing their ability in protecting polymorphism, is likely to contribute to the rate of decrease of MHC polymorphism.

The loss of rare alleles owing to drift would be facilitated by an increase in the allele frequency providing resistance to contemporary parasites in small populations (Sanjuán and Domingo-Calap, 2019). These unusual alleles would have been preserved in big populations, and many of them can be momentarily unfavorable (given the existing parasite genotype composition), lowering average population fitness (Loewe and Hill, 2010). As a result, population fitness should improve when such rare unfavorable alleles are lost due to drift. Additionally, if highly diverse alleles are preserved, a population's ability to resist pathogens may be significantly enhanced. However, as MHC alleles are lost and parasites evolve, host fitness falls below that of pre-bottleneck levels, as host mutations are ineffective in restoring the most resistant alleles (Ejmond and Radwan, 2011), raising the need to maintain the MHC's diversity.

Reduced MHC variation may render endangered populations more susceptible to disease and negatively impact their capability to elicit immune responses to emerging diseases (Siddle et al., 2007). If highly divergent alleles are retained, a population's ability to respond to pathogens may be significantly improved. However, simulations indicate that the maintenance of functional diversity in endangered species is not reliable (Ejmond and Radwan, 2011).

How to protect MHC diversity

The MHC diversity just like any other polymorphism can be substantially reduced by incidental bottlenecks, but as the population grows larger, selection and mutation restore variance to pre-bottleneck levels. MHC

diversity has been recovered via mutation in American moose (*Alces alces*), which experienced a population bottleneck during the Pleistocene glaciations (Mikko and Andersson, 1995). Selection does not tend to maintain a significant increase in MHC allele diversity, making it unlikely that endangered populations will be able to respond to emergent disease attacks. However, a swift recovery in population size may allow selection to retain or restore MHC variation provided suitable conservation measures are applied quickly enough (Ejzmond and Radwan, 2011).

Conclusion

As the debate lingers on whether it is the type (quality) of MHC or its quantity of diversity that confers protection on individuals and/or populations, there is a dire need to protect the present diversity at the locus. This will definitely play a very important role in maintaining the health of both humans and animals and ensure the conservation of biodiversity in response to the inevitable changes in our world.

Captive breeding programs as a strategy for wildlife conservation need to consider MHC polymorphism. The success of this program depends largely on the adaptive fitness of the reared populations, therefore there is a need to increase the MHC polymorphism of individuals for such programs. The same is true for ex-situ conservation strategies (in zoos and other wildlife sanctuaries) and livestock industries since the goal is a healthy environment altogether.

It is recommended that more quality research be directed towards the diversity of MHC in human and wildlife populations (especially at the community level rather than isolated studies of species) as it holds the key to their survival in the long run. Also, the influence of the diversity within the MHC on the survival of natural populations, especially on disease resistance begs for further studies.

Author Contributions

OMC conceptualized the title, sub-titles and contributed to the literature search and review. OHO contributed to the literature search and formatting while AOF contributed to the literature search, review and formatting.

Conflict of Interest

There is no conflict of interest that may influence or be perceived to influence this work.

References

- Akiyama T. Kohyama TI. Nishida C. Onuma M. Momose K. Masuda R 2017.** Genetic variation of major histocompatibility complex genes in the endangered red-crowned crane. *Immunogenetics*, 69(7), 451–462. DOI:10.1007/s00251-017-0994-6
- Al Hadra B. Lukanov TI and Ivanova MI 2022.** HLA class I chain-related MICA and MICB genes polymorphism in healthy individuals from the Bulgarian population. *Human Immunology*, 83(7), 551–555 ISSN 0198-8859. DOI:10.1016/j.humimm.2022.04.006
- Alcaide M. Lemus JA. Blanco G. Tella JL. Serrano D. Negro JJ. Rodriguez A. Garcia-Montijano M 2010.** MHC diversity and differential exposure to pathogens in kestrels Aves: Falconidae) *Molecular Ecology*, 19, 691–705. DOI:10.1111/j.1365-294X.2009.04507.x.
- Amiel JL. 1967.** Study of leucocyte phenotypes in Hodgkins' disease. *Histocompatibility testing 1967* 79-81.
- Averdam A. Kuschal C. Otto N. Westphal N. Roos C. Reinhardt R. Walter L 2011.** Sequence analysis of the grey mouse lemur (*Microcebus murinus*) MHC class II DQ and DR region. *Immunogenetics*, 63:85–93. DOI:10.1007/s00251-010-0487-3
- Babik W. Durka W. and Radwan J. 2005.** Sequence diversity of the MHC DRB gene in the Eurasian beaver *Castor fiber* *Molecular Ecology*, 14: 4249–4257. DOI:10.1111/j.1365-294x.2005.02751.x

- Becker L. Nieberg C. Jahreis K and Peters E. 2009.** MHC class II variation in the endangered European mink *Mustela lutreola* L. 1761)—Consequences for species conservation. *Immunogenetics*, 61, 281–288. DOI:10.1007/s00251-009-0362-2
- Biedrzycka A and Radwan J 2008.** Population fragmentation and major histocompatibility complex variation in the spotted suslik *Spermophilus suslicus*. *Molecular Ecology*, 17, 4801–4811. DOI:10.1111/j.1365-294X.2008-03955.x
- Bose B. Johnson DV. Campbell SB 2013.** Transplantation antigens and histocompatibility matching. In: Rath T ed. *Current Issues and Future Direction in Kidney Transplantation*. InTech, 371–90. ISBN: 978-953-51-0985-3.
- Bowen L. Aldridge BM. Gulland F. Van Bonn W. DeLong R. Melin S. Johnson ML 2004.** Class II multiformity generated by variable MHC-DRB region configurations in the California sea lion *Zalophus californianus* *Immunogenetics*, 56: 12–27. DOI:10.1007/s00251-004-0655-4
- Bravo MJ. Colmenero JD. Martín J. Alonso A. Caballero A 2007.** Polymorphism of the transmembrane region of the MICA gene and human brucellosis. *Tissue Antigens* 69: 358–360. PMID: 17389022. DOI: 10.1111/j.1399-0039.2007-00823.x
- Brewerton DA. Hart FD. Nicholls A. Caffrey M. James DCO. Sturrock RD 1973.** Ankylosing Spondylitis and HL-A 27. *The Lancet* 301(7809) 904–907. DOI:10.1016/s0140-6736(73)91360-3
- Burri R. Salamin N. Studer RA. Roulin A. Fumagalli L 2010.** Adaptive divergence of ancient gene duplicates in the avian MHC class II beta. *Molecular Biology and Evolution*, 27 2360–2374. DOI: 10.1093/molbev/msq120
- Castillo S. Srithayakumar V. Meunier V. Kyle CJ 2010.** Characterization of Major Histocompatibility Complex (MHC) DRB Exon 2 and DRA Exon 3 Fragments in a Primary Terrestrial Rabies Vector *Procyon lotor* *PLoS ONE* 5(8): e12066. DOI:10.1371/journal.pone.0012066
- Castro-Prieto A. Wachter B. Sommer S 2011.** Cheetah Paradigm Revisited: MHC Diversity in the World's Largest Free-Ranging Population *Molecular Biology and Evolution*, 28(4):1455–1468. 2011. DOI: 10.1093/molbev/msq330
- Chu X. Yang M. Song ZJ. Dong Y. Li C. Shen M. Huang W 2018.** Fine mapping MHC associations in Graves' disease and its clinical subtypes in Han Chinese. *Journal of Medical Genetics*, 0:1–8. DOI:10.1136/jmedgenet-2017-105146
- Cohen R. Metzger S. Nahir M. Chajek-Shaul T 2002.** Association of the MIC-A gene and HLA-B51 with Behçet's disease in Arabs and non-Ashkenazi Jews in Israel. *Annals of the Rheumatic Diseases* 61: 157–160. PMID: 11796403. DOI: 10.1136/ard.61.2.157
- Dadi H. Le M. Dinka H. Nguyen D. Choi H. Cho H. Park C 2015.** Genetic Diversity and mRNA Expression of Porcine MHC Class I Chain-Related 2 (SLA-MIC2) Gene and Development of a High-Resolution Typing Method. *PLOS ONE* 10(8) e0135922. DOI: 10.1371/journal.pone.0135922
- De Bruyn M. Allendorf FW. Luikart G 2007.** Conserving Global Biodiversity? Conservation and the Genetics of Populations. *Conservation Genetics*, 9(2) 437–438. DOI:10.1007/s10592-007-9330-2
- De Groot N. Stanbury K. de Vos-Rouweler AJM. de Groot NG. Poirier N. Blancho G. Bontrop RE 2017.** A quick and robust MHC typing method for free-ranging and captive primate species. *Immunogenetics*, 69(4) 231–240. DOI:10.1007/s00251-016-0968-0
- De la Herrán-Arita AK and García-García F 2014.** Narcolepsy as an Immune-Mediated Disease. *Sleep Disorders*, 1–6. DOI:10.1155/2014/792687
- Delgado JC. Yunis DE. Bozón MV. Salazar M. Deulofeut R. Turbay D. Yunis EJ 1996.** MHC class II alleles and haplotypes in patients with pemphigus vulgaris from India. *Tissue Antigens*, 48(6), 668–672. DOI:10.1111/j.1399-0039.1996-tb02690.x
- Ejzmond MJ and Radwan J 2011.** MHC diversity in bottlenecked populations: a simulation model. *Conservation Genetics*, 12:129–137 DOI 10.1007/s10592-009-9998-6
- Evans ML. Neff BD. Heath DD 2009.** MHC genetic structure and divergence across populations of Chinook salmon *Oncorhynchus tshawytscha*. *Heredity*, 104(5), 449–459. DOI:10.1038/hdy.2009.121

- Fernando MMA, Freudenberg J, Lee A, Morris DL, Boteva L, Rhodes B 2012.** Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5 HLA-DPB1 and HLA-G. *Annals of the Rheumatic Diseases*, 71(5) 777–784. DOI:10.1136/annrheumdis-2011-200808
- Fernando MMA, Stevens CR, Sabeti PC, Walsh EC, McWhinnie AJM, Shah A, Vyse TJ 2007.** Identification of Two Independent Risk Factors for Lupus within the MHC in United Kingdom Families. *PLoS Genetics*, 3(11) e192. DOI: 10.1371/journal.pgen.0030192
- Fleischnick E, Raum D, Alosco S, Gerald P, Yunis E, Awdeh Z, Alper C 1983.** Extended Mhc Haplotypes In 21-Hydroxylase-Deficiency Congenital Adrenal Hyperplasia: Shared Genotypes in Unrelated Patients. *The Lancet*, 321(8317), 152–156. DOI:10.1016/s0140-
- Froeschke G and Sommer S 2005.** MHC Class II DRB constitution and parasite load in the striped mouse *Rhabdomys pumilio* in the Southern Kalahari. *Molecular Biology and Evolution*. 22:1254-1259. DOI.org/10.1093/molbev/msi112
- Gaigher A, Burri R, Gharib W, Taberlet P, Roulin A, Fumagalli L. 2016.** Family-assisted inference of the genetic architecture of major histocompatibility complex variation. *Molecular Ecology Resources*, 16(6), 1353–1364. DOI: 10.1111/1755-0998.12537
- Gorodezky C, Alaez C, Munguía A, Cruz R, Vazquez A, Camacho A, Rodriguez O 2004.** Molecular mechanisms of MHC linked susceptibility in leprosy: towards the development of synthetic vaccines. *Tuberculosis*. 84(1-2), 82–92. DOI:10.1016/j.tube.2003.08.00
- Gutierrez-Achury J, Zhernakova A, Pulit SL, Trynka G, Hunt KA, Romanos J, de Bakker PIW 2015.** Fine mapping in the MHC region accounts for 18% additional genetic risk for celiac disease. *Nature Genetics*, 47(6), 577–578. DOI:10.1038/ng.3268
- Hedrick P 2003.** The major histocompatibility complex (MHC) in declining populations: An example of adaptive variation. In W. V. Holt A. R. Pickard J. C. Rodger and D. E. Wildt Eds.) *Reproduction science and integrated conservation* pp. 97–113 Cambridge UK: Cambridge University Press.
- Hedrick PW 2002.** Pathogen resistance and genetic variation at MHC loci. *Evolution*, 56: 1902–1908. DOI: 10.1111/j.0014-3820.2002.tb00116.x
- Hedrick PW and Thomson G 1988.** Maternal-Fetal Interactions and the Maintenance of HLA Polymorphism. *Genetics* 119: 206-212. DOI: 10.1093/genetics/119.1.205
- Hjelmström P and Sanjeevi CB 2000.** Molecular Mechanisms of MHC Associations with Myasthenia Gravis. In: Christadoss P. eds) *Myasthenia Gravis*. Springer Dordrecht. DOI: 10.1007/978-94-011-4060-7_9
- Holderegger R, Kamm U, Gugerli F 2006.** Adaptive vs. neutral genetic diversity: implications for landscape genetics. *Landsc Ecol* 21: 797-807. *Landscape Ecology*. 21(6), 797-807. DOI:10.1007/s10980-005-5245-9
- Howell WM 2013.** HLA and disease: guilt by association. *International Journal of Immunogenetics*, 41(1), 1–12. DOI:10.1111/iji.12088
- Huchard E, Cowlshaw G, Raymond MI, Weill M, Knapp LA 2006.** Molecular study of Mhc-DRB in wild chacma baboons reveals high variability and evidence for trans-species inheritance. *Immunogenetics*, 58: 805–816. DOI: 10.1007/s00251-006-0156-8
- Hughes AL and Hughes MK 1995.** Natural selection on the peptide-binding regions of major histocompatibility complex molecules. *Immunogenetics* 42: 233–243. DOI: 10.1007/BF00176440
- Hughes AL, Ota T, Nei M 1990.** Positive Darwinian selection promotes charge profile diversity in the antigen-binding cleft of class I major-histocompatibility-complex molecules. *Mol. Biol. Evol.* 7 515–524. DOI: 10.1093/oxfordjournals.molbev.a040626
- Janeway Jr CA, Travers P, Walport M, Shlomchik MJ 2001.** *Immunobiology: The Immune System in Health and Disease*. 5th edition. New York: Garland Science. The Front Line of Host Defense. <https://www.ncbi.nlm.nih.gov/books/NBK27105/>
- Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Dranoff G 2008.** MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple

- myeloma. *Proceedings of the National Academy of Sciences*, 105(4) 1285–1290. DOI:10.1073/pnas.0711293105
- Judson MA. 2018.** A sarcoidosis clinician’s perspective of MHC functional elements outside the antigen binding site. *Human Immunology*. DOI:10.1016/j.humimm.2018.05.007
- Kalbe M. Eizaguirre C. Dankert I. Reusch TBH. Sommerfeld RD. Wegner KM. Milinski M 2009.** Lifetime reproductive success is maximized with optimal major histocompatibility complex diversity. *Proceedings of the Royal Society of London Series B: Biological Sciences* 276 925–934. DOI:10.1098/rspb.2008.1466
- Kelly A and Trowsdale J 2017.** Introduction: MHC/KIR and governance of specificity. *Immunogenetics* 69(8-9) 481–488. DOI:10.1007/s00251-017-0986-6
- Khor CC. Chau TNB. Pang J. Davila S. Long HT. Ong RTH. Simmons CP 2011.** Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. *Nature Genetics* 43(11) 1139–1141. DOI:10.1038/ng.960
- Kohyama TI. Akiyama T. Nishida C. Takami K. Onuma M. Momose K. Masuda R 2015.** Isolation and characterization of major histocompatibility complex class II B genes in cranes. *Immunogenetics* 67: 705–710
- Lan H. Zhou T. Wan QH. Fang SG 2019.** Genetic Diversity and Differentiation at Structurally Varying MHC Haplotypes and Microsatellites in Bottlenecked Populations of Endangered Crested Ibis. 8(4), 377. DOI:10.3390/cells8040377
- Loewe L and Hill WG 2010.** The population genetics of mutations: good bad and indifferent. *Philosophical Transactions of the Royal Society B: Biological Sciences* 365(1544) 1153–1167. DOI:10.1098/rstb.2009.0317
- Madsen T and Ujvari B 2006.** MHC Class I associates with parasite resistance and longevity in tropical pythons. *Journal of Evolutionary Biology*, 19(6), 1973–1978. DOI: 10.1111/j.1420-9101.2006.01158.x
- Manlik O. Krützen M. Kopps AM. Mann J. Bejder L. Allen SJ. Sherwin WB 2019.** Is MHC diversity a better marker for conservation than neutral genetic diversity? A case study of two contrasting dolphin populations. *Ecology Evolution*, 9:6986–6998. DOI: 10.1002/ece3.5265
- Mason RA. Browning TL. Eldridge MDB 2011.** Reduced MHC class II diversity in island compared to mainland populations of the black-footed rock-wallaby *Petrogale lateralis lateralis*. *Conservation Genetics*, 12, 91–103. DOI 10.1007/s10592-009-9993-y
- Mikko S and Andersson L 1995.** Low major histocompatibility complex class II diversity in European and North American moose. *Proceedings of the National Academy of Sciences*. 92(10), 4259–4263. DOI:10.1073/pnas.92.10.4259
- Miller HC. Allendorf F. Daugherty CH 2010.** Genetic diversity and differentiation at MHC genes in island populations of tuatara *Sphenodon* spp. *Molecular Ecology*, 19, 3894–3908. DOI: 10.1111/j.1365-294X.2010.04771.x
- Milner CM. Smith SV. Carrillo MB. Taylor GL. Hollinshead M. Campbell RD 1997.** Identification of a Sialidase Encoded in the Human Major Histocompatibility Complex. *Journal of Biological Chemistry*, 272(7), 4549–4558. DOI:10.1074/jbc.272.7.4549
- Molinero LL. Fuertes MB. Rabinovich GA. Fainboim L. Zwirner NW 2002.** Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. *Journal of Leukocyte Biology*, 71: 791–797. PMID: 11994503
- Morran MP. Vonberg A. Khadra A. Pietropaolo M 2015.** Immunogenetics of type 1 diabetes mellitus. *Molecular Aspects of Medicine*, 42, 42–60. DOI:10.1016/j.mam.2014.12.004
- Morris KM. Wright B. Grueber CE. Hoggt C. Belov K 2015.** Lack of genetic diversity across diverse immune genes in an endangered mammal the Tasmanian devil *Sarcophilus harrisii* *Molecular Ecology*, 24, 3860–3872. DOI: 10.1111/mec.13291
- Newton J. Harney S. Wordsworth B. Brown M 2004.** A review of the MHC genetics of rheumatoid arthritis. *Genes & Immunity* 5(3) 151–157. DOI:10.1038/sj.gene.6364045

- Niskanen AK. Kennedy LJ. Ruokonen M. Kojola I. Lohi H. Isomursu M. Jansson E. Pyhäjärvi T. Aspi J 2014.** Balancing selection and heterozygote advantage in major histocompatibility complex loci of the bottlenecked Finnish wolf population. *Molecular Ecology*, 23:875–889. DOI: 10.1111/mec.12647
- Peacock MM and Smith AT 1997.** The effects of habitat fragmentation on dispersal patterns mating behavior and genetic variation in a pika (*Ochotona princeps*) metapopulation. *Oecologia*, 112:524–533. DOI:10.1007/s004420050341
- Piertney SB and Oliver MK 2006.** The evolutionary ecology of the major histocompatibility complex. *Heredity* 96: 7–21. DOI: 10.1038/sj.hdy.6800724
- Piertney SB and Webster LMI 2010.** Characterizing functionally important and ecologically meaningful genetic diversity using a candidate gene approach. *Genetica*, 138(4) 419–432. DOI:10.1007/s10709-008-9322-2
- Radwan J. Babik W. Kaufman J. Lenz TL. Winternitz J 2020.** Advances in the Evolutionary Understanding of MHC Polymorphism. *Trends in Genetics*, 36(4) DOI:10.1016/j.tig.2020.01.008
- Radwan J. Biedrzycka A. Babik W 2010.** Does reduced MHC diversity decrease viability of vertebrate populations? *Biology and Conservation*, 143:537–544. DOI: 10.1016/j.biocon.2009.07.026
- Ramagopalan SV and Ebers GC 2009.** Multiple sclerosis: major histocompatibility complexity and antigen presentation. *Genome Medicine*, 1(11), 105. DOI:10.1186/gm105
- Reche PA and Reinherz EL 2003.** Sequence variability analysis of human class I and class II MHC molecules: Functional and structural correlates of amino acid polymorphisms. *Journal of Molecular Biology*, 331, 623–641. DOI: 10.1016/s0022-2836(03)00750-2
- Reith W and Mach B 2001.** The Bare Lymphocyte Syndrome and The Regulation of MHC Expression. *Annual Review of Immunology*, 19(1), 331–373. DOI:10.1146/annurev.immunol.19.1.331
- Riley EM. Olerup O. Bennett S. Rowe P. Allen SJ. Blackman MJ. Greenwood BM 1992.** MHC and malaria: the relationship between HLA class II alleles and immune responses to *Plasmodium falciparum*. *International Immunology*, 4(9), 1055–1063. DOI:10.1093/intimm/4.9.1055
- Robinson J. Halliwell JA. Hayhurst JH. Flicek P. Parham P. Marsh SGE 2015.** The IPD and IMGT/HLA database: allele variant databases. *Nucleic Acids Research*, 43: D423–D431. DOI: 10.1093/nar/gku1161
- Sanjuán R and Domingo-Calap P 2019.** Genetic Diversity and Evolution of Viral Populations. Reference Module in Life Sciences. DOI:10.1016/b978-0-12-809633-8.20958-8
- Schwensow N. Fietz J. Dausmann KH. Sommer S 2007.** Neutral versus adaptive genetic variation in parasite resistance: importance of major histocompatibility complex supertypes in a free-ranging primate. *Heredity*, 99: 265–277. DOI: 10.1038/sj.hdy.6800993
- Sommer S. 2005.** The importance of immune gene variability MHC in evolutionary ecology and conservation. *Frontiers in Zoology*. 2005, 2:16. DOI: 10.1186/1742-9994-2-16
- Thoss M. Ilmonen K. Musolf K. Penn DJ 2011.** Major histocompatibility complex heterozygosity enhances reproductive success. *Molecular Ecology*, 20, 1546–1557. DOI.org/10.1111/j.1365294X.2011-05009.x
- Truedsson L. Alper CA. Awdeh ZL. Johansen P. Sjöholm AG Sturfelt G 1993.** Characterization of type I complement C2 deficiency MHC haplotypes. Strong conservation of the complement/HLA-B-region and absence of disease association due to linked class II genes. *Journal of Immunology*, 15; 151(10):5856-63. PMID: 7901282.
- Tsai S and Santamaria P 2013.** MHC class II polymorphisms autoreactive T-cells and Autoimmunity. *Frontiers in Immunology. Antigen Presenting Cell Biology*, 4:321 DOI: 10.3389/fimmu.2013.00321
- Tsuji H. Taniguchi Y. Ishizuka S. Matsuda H. Yamada T. Naito K. Iwaisaki H 2017.** Structure and polymorphisms of the major histocompatibility complex in the Oriental stork *Ciconia boyciana*. *Sci. Rep.* 2017 7 42864.
- Ujvari B and Belov K 2011.** Major Histocompatibility Complex (MHC) Markers in Conservation Biology. *International Journal of Molecular Sciences*, 12, 5168–5186. DOI:10.3390/ijms12085168

- Walford RL. Finkelstein S. Neerhout R. Konrad P. Shanbrom E 1970.** Acute Childhood Leukaemia in Relation to the HL-A Human Transplantation Genes. *Nature*, 225(5231), 461–462. DOI:10.1038/225461a0
- Wang N. Shen N. Vyse TJ. Anand V. Gunnarson I. Sturfelt G. Hammarström L 2011.** Selective IgA Deficiency in Autoimmune Diseases. *Molecular Medicine*, 17(11-12) 1383–1396. DOI:10.2119/molmed.2011.00195
- Wang S. Liu C. Wilson AB. Zhao N. Li X. Zhu W. Gao X. Liu X. Li Y 2017.** Pathogen richness and abundance predict patterns of adaptive MHC variation in insular amphibians. *Molecular Ecology*, 26, 4671–4685. DOI: 10.1111/mec.14242
- Weber DS. Stewart BS. Schienman J. Lehman N 2004.** Major histocompatibility complex variation at three class II loci in the northern elephant seal. *Molecular Ecology*, 13(3), 711–718. DOI:10.1111/j.1365-294x.2004-02095.x
- Wong CGT. Scherer SW. Snead III OC. Hampson DR 2001.** Localization of the human mGluR4 gene within an epilepsy susceptibility locus. *Molecular Brain Research*, 87(1), 109–116. DOI:10.1016/s0169-328x(00)00283-7
- Yamaguchi T and Dijkstra JM 2019.** Major Histocompatibility Complex (MHC) Genes and Disease Resistance in Fish. *Cells*, 8(4), 378. DOI:10.3390/cells8040378
- Zeisset I and Beebe TJ 2009.** Molecular characterization of major histocompatibility complex class II alleles in the common frog *Rana temporaria*. *Molecular Ecology Resources*, 9: 738–745. DOI.org/10.1111/j.1755-0998.2009-02535.x
- Zeng CJ. Pan HJ. Gong SB. Yu JQ. Wan QH. Fang SG 2007.** Giant panda BAC library construction and assembly of a 650-kb contig spanning major histocompatibility complex class II region. *BMC Genomics*, 8: 315. DOI:10.1186/1471-2164-8-315
- Zhang J. Wei Z. Cardinale CJ. Gusareva ES. Van Steen K. Sleiman P 2019.** Multiple Epistasis Interactions Within MHC Are Associated With Ulcerative Colitis. *Frontiers in Genetics*, 10. DOI:10.3389/fgene.2019.00257
- Zhou F and Zhang X 2018.** Major Histocompatibility Complex and Psoriasis. *Journal of Investigative Dermatology Symposium Proceedings*, 19(2), S79–S80. DOI:10.1016/j.jisp.2018.09.006
- Ziegler A. Kentenich H. Uchanska-Ziegler B 2005.** Female choice and the MHC. *Trends in Immunology*, 26:496–502. DOI: 10.1016/j.it.2005.07.003